Immuron (Immuron) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Immuron Debt-to-Equity?

Immuron's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Immuron's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Immuron's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $11.73 Mil. Immuron's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Immuron's Debt-to-Equity or its related term are showing as below:

IMRN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.39
Current: 0.01

During the past 9 years, the highest Debt-to-Equity Ratio of Immuron was 0.39. The lowest was 0.00. And the median was 0.01.

IMRN's Debt-to-Equity is ranked better than
99.91% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs IMRN: 0.01

Immuron Debt-to-Equity Historical Data

The historical data trend for Immuron's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Debt-to-Equity Chart

Immuron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

Immuron Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial												0.01	0.01	0.01	0.01	-

Competitive Comparison of Immuron's Debt-to-Equity

For the Biotechnology subindustry, Immuron's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immuron's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Immuron's Debt-to-Equity falls into.

Immuron Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Immuron's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.026	+	0.101)	/	13.166
	=	0.01

Immuron's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	11.732
	=	0.00

Immuron (NAS:IMRN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Immuron Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Immuron's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron (Immuron) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (NAS:IMRN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ANWA:Germany IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.